Sanofi India share news, announcements and annual reports
NSE: SANOFIBSE: 500674Pharmaceuticals & BiotechnologySmall Cap
Sanofi India Limited · Formerly Aventis Pharma · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1984 on BSE, May 2003 on NSE
Last close ₹3,204.10up ₹14.60 (0.46%)BSE ₹3,204.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹3,189.50.
30 Oct: open ₹3,265.00, high ₹3,422.60, low ₹3,175.10
52-week range of traded prices to 30 Oct 2026
₹2,758.20Low, 23 Oct 2026₹4,834.00High, 30 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,379 Cr614th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 20.24
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 8.93
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 3.84%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 45.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 57.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Jun 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,04,44220.0% delivered
Sanofi India disputes and clarifications
19 filed, newest first.
Sep 2026
Aug 2026
Mar 2025
7 Mar · Legal
Exchange has sought clarification from Sanofi India Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. The response of the Company is awaited.
Dec 2024
6 Dec · Legal
Exchange has sought clarification from Sanofi India Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Nov 2024
Jul 2023
3 Jul · Legal
Exchange has sought clarification from Sanofi India Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Feb 2019
Nov 2018
Mar 2017
2 Mar · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned "Sanofi, Boehringer close business swap"In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
May 2016
12 May · Legal
Jan 2015
30 Jan · Legal
Exchange had sought clarification from Sanofi India Limited with respect to a news item captioned "Sanofi to set up insulin plant near Hyderabad". The Company has clarified that "The plant is being set up by Shantha Biotechnics Private Limited, a subsidiary of Sanofi, SA, France".30 Jan · Legal
Exchange has sought clarification from Sanofi India Limited with respect to recent news item captioned "Sanofi to set up insulin plant near Hyderabad . In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.